Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

61. Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcome

Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcome 28655834 2017 06 28 2017 09 06 1524-4539 136 10 2017 Sep 05 Circulation Circulation Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (...) (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). 907-916 10.1161/CIRCULATIONAHA.117.028566 Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or

EvidenceUpdates2017

62. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. Background We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. Methods In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily (...) ). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. Results The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=-4.126), but major bleeding events occurred in more

NEJM2017

63. Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus

Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus 28718829 2018 11 13 2227-9059 5 3 2017 Jul 18 Biomedicines Biomedicines Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus. E43 10.3390/biomedicines5030043 Overwhelming evidence indicates that aspirin and related non-steroidal anti-inflammatory drugs (NSAIDs) have anti-tumour activity and the potential to prevent cancer, particularly colorectal cancer. However, the mechanisms (...) Research United Kingdom MR/J001481/1 Medical Research Council United Kingdom Journal Article Review 2017 07 18 Switzerland Biomedicines 101691304 2227-9059 Aspirin RelA apoptosis colon cancer non-steroidal anti-inflammatory drugs nuclear factor kappaB nucleolar nucleoli nucleolus p65 sequestration stress The authors declare no conflict of interest. 2017 06 20 2017 07 07 2017 07 13 2017 7 19 6 0 2017 7 19 6 0 2017 7 19 6 1 epublish 28718829 biomedicines5030043 10.3390/biomedicines5030043 PMC5618301 Mol

Biomedicines2017 Full Text: Link to full Text with Trip Pro

64. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.

Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. Background Preterm preeclampsia is an important cause of maternal and perinatal death and complications. It is uncertain whether the intake of low-dose aspirin during pregnancy reduces the risk of preterm preeclampsia. Methods In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1776 women with singleton pregnancies who were at high risk for preterm preeclampsia to receive aspirin, at (...) a dose of 150 mg per day, or placebo from 11 to 14 weeks of gestation until 36 weeks of gestation. The primary outcome was delivery with preeclampsia before 37 weeks of gestation. The analysis was performed according to the intention-to-treat principle. Results A total of 152 women withdrew consent during the trial, and 4 were lost to follow up, which left 798 participants in the aspirin group and 822 in the placebo group. Preterm preeclampsia occurred in 13 participants (1.6%) in the aspirin group

NEJM2017

65. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. Background Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin. Methods In this randomized, double-blind, phase 3 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin. All the study patients had (...) (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%) receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both comparisons). Rates of major bleeding were 0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg

NEJM2017

66. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.

Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. BACKGROUND: Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, is the standard antithrombotic treatment following acute coronary syndromes. The factor Xa inhibitor rivaroxaban reduced mortality and ischaemic events when added to DAPT, but caused increased bleeding. The safety of a dual (...) pathway antithrombotic therapy approach combining low-dose rivaroxaban (in place of aspirin) with a P2Y12 inhibitor has not been assesssed in acute coronary syndromes. We aimed to assess rivaroxaban 2·5 mg twice daily versus aspirin 100 mg daily, in addition to clopidogrel or ticagrelor (chosen at investigator discretion before randomisation), for patients with acute coronary syndromes started within 10 days after presentation and continued for 6-12 months. METHODS: In this double-blind, multicentre

Lancet2017

68. Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials

Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials 27627817 2016 09 14 2016 11 15 1528-1175 125 6 2016 Dec Anesthesiology Anesthesiology Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials. 1121-1129 The PeriOperative ISchemia Evaluation-2 (POISE-2) trial compared aspirin with placebo (...) after noncardiac surgery. The authors randomly assigned 10,010 patients undergoing noncardiac surgery to receive 200 mg aspirin or placebo 2 to 4 h before surgery and then 100 mg aspirin daily or placebo daily for up to 30 days after surgery. Herein, the authors report the effect of aspirin on venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, as well as an updated pooled analysis of randomized trials of antiplatelet therapy for VTE prevention in noncardiac surgery

EvidenceUpdates2016

69. Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial

Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial 27741174 2016 10 14 2017 02 03 1873-233X 128 5 2016 Nov Obstetrics and gynecology Obstet Gynecol Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial. 1053-1063 To evaluate whether daily enoxaparin, added to low-dose aspirin, started before 14 weeks of gestation reduces placenta (...) 100 mg aspirin or 100 mg aspirin alone. Randomization was done by a web-based randomization system. The primary composite outcome comprised maternal death, perinatal death, preeclampsia, small for gestational age (less than the 10th percentile), and placental abruption. A sample size of 232 women equally divided into two groups was needed to detect a significant reduction in primary outcome from 55% in the aspirin group to 36.7% in the enoxaparin-aspirin group (α: 0.05, β: 0.8, two-sided). Between

EvidenceUpdates2016

71. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm

Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm 27576775 2016 09 20 2017 04 25 2017 04 25 1524-4539 134 12 2016 Sep 20 Circulation Circulation Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular (...) Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). 861-71 10.1161/CIRCULATIONAHA.116.024637 In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

72. Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone

Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone 27418597 2016 08 23 2017 05 15 2017 05 15 1524-4628 47 9 2016 Sep Stroke Stroke Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. 2323-30 10.1161/STROKEAHA.115.012293 In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent (...) recurrent cerebral ischemia. However, there is no clear evidence. In this multicenter, double-blind, placebo-controlled trial, we randomized 358 patients with acute ischemic stroke of presumed large artery atherosclerosis origin within 48 hours of onset to clopidogrel (75 mg/d without loading dose) plus aspirin (300-mg loading followed by 100 mg/d) or to aspirin alone (300-mg loading followed by 100 mg/d) for 30 days. The primary outcome was new symptomatic or asymptomatic ischemic lesion

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

73. Aspirin before Coronary Artery Surgery.

Aspirin before Coronary Artery Surgery. Aspirin before Coronary Artery Surgery. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27406359 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jul 7;375(1):91-2. doi: 10.1056/NEJMc1603852. Aspirin before Coronary Artery Surgery. , , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27406359 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment: Supplemental

NEJM2016 Full Text: Link to full Text with Trip Pro

74. Aspirin before Coronary Artery Surgery.

Aspirin before Coronary Artery Surgery. Aspirin before Coronary Artery Surgery. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27406360 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jul 7;375(1):90-1. doi: 10.1056/NEJMc1603852#SA1. Aspirin before Coronary Artery Surgery. 1 , 1 . 1 University of British Columbia, Vancouver, BC, Canada alkhodair@alumni.ubc.ca. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27406360 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical

NEJM2016 Full Text: Link to full Text with Trip Pro

75. Aspirin before Coronary Artery Surgery.

Aspirin before Coronary Artery Surgery. Aspirin before Coronary Artery Surgery. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27406361 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jul 7;375(1):91. doi: 10.1056/NEJMc1603852#SA2. Aspirin before Coronary Artery Surgery. 1 , 1 , 1 . 1 Radboud University Medical Center, Nijmegen, the Netherlands wilson.li@radboudumc.nl. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27406361 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources

NEJM2016 Full Text: Link to full Text with Trip Pro

76. Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial.

Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial. 27179988 2016 06 15 2016 06 22 2017 04 08 1538-3598 315 22 2016 Jun 14 JAMA JAMA Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial. 2406-14 10.1001/jama.2016.6330 Management of acute respiratory distress syndrome (ARDS) remains largely supportive. Whether early (...) intervention can prevent development of ARDS remains unclear. To evaluate the efficacy and safety of early aspirin administration for the prevention of ARDS. A multicenter, double-blind, placebo-controlled, randomized clinical trial conducted at 16 US academic hospitals. Between January 2, 2012, and November 17, 2014, 7673 patients at risk for ARDS (Lung Injury Prediction Score ≥4) in the emergency department were screened and 400 were randomized. Ten patients were excluded, leaving 390 in the final

JAMA2016 Full Text: Link to full Text with Trip Pro

77. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.

Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. BACKGROUND: Ticagrelor may be a more effective antiplatelet therapy than aspirin for the prevention of recurrent stroke and cardiovascular events in patients with acute cerebral ischemia. METHODS: We conducted an international double-blind, controlled trial in 674 centers in 33 countries, in which 13,199 patients with a nonsevere ischemic stroke or high-risk transient ischemic attack who had not received intravenous (...) or intraarterial thrombolysis and were not considered to have had a cardioembolic stroke were randomly assigned within 24 hours after symptom onset, in a 1:1 ratio, to receive either ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2 through 90) or aspirin (300 mg on day 1 followed by 100 mg daily for days 2 through 90). The primary end point was the time to the occurrence of stroke, myocardial infarction, or death within 90 days. RESULTS: During the 90 days of treatment

NEJM2016

78. Complications and Safety of Preconception Low-Dose Aspirin Among Women With Prior Pregnancy Losses

Complications and Safety of Preconception Low-Dose Aspirin Among Women With Prior Pregnancy Losses 26959198 2016 03 24 2016 08 08 2017 04 03 1873-233X 127 4 2016 Apr Obstetrics and gynecology Obstet Gynecol Complications and Safety of Preconception Low-Dose Aspirin Among Women With Prior Pregnancy Losses. 689-98 10.1097/AOG.0000000000001301 To evaluate complications and safety of preconception low-dose aspirin in 1,228 U.S. women (2007-2011). Evaluation of the safety of low-dose aspirin in (...) the participants and their fetuses was a planned secondary analysis of the Effects of Aspirin in Gestation and Reproduction trial, a multicenter, block-randomized, double-blind, placebo-controlled trial investigating the effect of low-dose aspirin on the incidence of live birth. Women aged 18-40 years with a history of one to two pregnancy losses trying to conceive were randomized to daily low-dose aspirin (81 mg, n=615) or placebo (n=613) and were followed for up to six menstrual cycles or through gestation

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

79. Aspirin resistance in coronary heart disease: Current understandings and strategies

Aspirin resistance in coronary heart disease: Current understandings and strategies 28191510 2018 11 13 2450-131X 4 1 2016 Apr 01 Journal of translational internal medicine J Transl Int Med Aspirin resistance in coronary heart disease: Current understandings and strategies. 7-10 10.1515/jtim-2016-0002 Han Ya-Ling YL Department of Cardiology, General Hospital of Shenyang Military Command, Shenyang 110016, Liaoning Province, China. eng Journal Article 2016 04 14 Germany J Transl Int Med 101673826

Journal of translational internal medicine2016 Full Text: Link to full Text with Trip Pro

80. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.

Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. BACKGROUND: Evidence indicates that aspirin is effective for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) but also increases the risk for gastrointestinal (GI) and cerebral hemorrhages. OBJECTIVE: To assess the net balance of benefits and harms from routine aspirin use across clinically relevant age, sex (...) , and CVD risk groups. DESIGN: Decision analysis using a microsimulation model. DATA SOURCES: 3 systematic evidence reviews. TARGET POPULATION: Men and women aged 40 to 79 years with a 10-year CVD risk of 20% or less, and no history of CVD and without elevated risk for GI or cerebral hemorrhages that would contraindicate aspirin use. TIME HORIZON: Lifetime, 20 years, and 10 years. PERSPECTIVE: Clinical. INTERVENTION: Low-dose aspirin (≤100 mg/d). OUTCOME MEASURES: Primary outcomes are length and quality

Annals of Internal Medicine2016 Full Text: Link to full Text with Trip Pro